2018 대한부정맥학회 심방세동 환자에서 NOAC 사용 지침: 출혈의 대처와 수술 전후 복약관리

키워드

참고문헌 (56)

1. Connolly SJ, "Dabigatran versus warfarin in patients with atrial fibrillation", N Engl J Med, 361, pp.1139~1151 (2009)
2. Patel MR, "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation", N Engl J Med, 365, pp.883~891 (2011)
3. Granger CB, "Apixaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 365, pp.981~992 (2011)
4. Giugliano RP, "Edoxaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 369, pp.2093~2104 (2013)
5. Lee SR, "Temporal trends of antithrombotic therapy for stroke prevention in Korean patients with non-valvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants : a nationwide population-based study", PLoS One, 12, pp.e0189495~ (2017)
6. Ruff CT, "Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation : a meta-analysis of randomised trials", Lancet, 383, pp.955~962 (2014)
7. Pollack CV Jr, "Idarucizumab for dabigatran reversal-full Cohort analysis", N Engl J Med, 377, pp.431~441 (2017)
8. Connolly SJ, "Andexanet alfa for acute major bleeding associated with factor Xa inhibitors", N Engl J Med, 375, pp.1131~1141 (2016)
9. Enriquez A, "Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants", Europace, 18, pp.955~964 (2016)
10. Hylek EM, "Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin : the ARISTOTLE Trial(apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation) : predictors, characteristics, and clinical outcomes", J Am Coll Cardiol, 63, pp.2141~2147 (2014)
11. Piccini JP, "Management of major bleeding events in patients treated with rivaroxaban vs. warfarin:results from the ROCKET AF trial", Eur Heart J, 35, pp.1873~1880 (2014)
12. Majeed A, "Management and outcomes of major bleeding during treatment with dabigatran or warfarin", Circulation, 128, pp.2325~2332 (2013)
13. Majeed A, "Management of rivaroxaban-or apixaban-associated major bleeding with prothrombin complex concentrates : a cohort study", Blood, 130, pp.1706~1712 (2017)
14. Healey JS, "Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin : results from the randomized evaluation of long-term anticoagulation therapy(RE-LY)randomized trial", Circulation, 126, pp.343~348 (2012)
15. Godier A, "Predictors of pre-procedural concentrations of direct oral anticoagulants : a prospective multicentre study", Eur Heart J, 38, pp.2431~2439 (2017)
16. Douketis JD, "The perioperative anticoagulant use for surgery evaluation(PAUSE)study for patients on a direct oral anticoagulant who need an elective surgery or procedure : design and rationale", Thromb Haemost, 117, pp.2415~2424 (2017)
17. Douketis JD, "Perioperative bridging anticoagulation in patients with atrial fibrillation", N Engl J Med, 373, pp.823~833 (2015)
18. Sivolella S, "Managing dentoalveolar surgical procedures in patients taking new oral anticoagulants", Odontology, 103, pp.258~263 (2015)
19. Johnston S, "An evidence summary of the management of patients taking direct oral anticoagulants(DOACs)undergoing dental surgery", Int J Oral Maxillofac Surg, 45, pp.618~630 (2016)
20. Mauprivez C, "Management of dental extraction in patients undergoing anticoagulant oral direct treatment : a pilot study", Oral Surg Oral Med Oral Pathol Oral Radiol, 122, pp.e146~e155 (2016)
21. Patel JP, "Managing direct oral anticoagulants in patients undergoing dentoalveolar surgery", Br Dent J, 222, pp.245~249 (2017)
22. Yagyuu T, "Risks of postextraction bleeding after receiving direct oral anticoagulants or warfarin : a retrospective cohort study", BMJ Open, 7, pp.e015952~ (2017)
23. Miclotte I, "Pragmatic approach to manage new oral anticoagulants in patients undergoing dental extractions : a prospective case-control study", Clin Oral Investig, 21, pp.2183~2188 (2017)
24. Birnie DH, "Pacemaker or defibrillator surgery without interruption of anticoagulation", N Engl J Med, 368, pp.2084~2093 (2013)
25. Birnie DH, "Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2)", Eur Heart J, 39, pp.3973~3979 (2018)
26. Narouze S, "Interventional spine and pain procedures in patients on antiplatelet and anticoagulant medications : guidelines from the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain", Reg Anesth Pain Med, 40, pp.182~212 (2015)
27. Albaladejo P, "Management of direct oral anticoagulants in patients undergoing elective surgeries and invasive procedures : updated guidelines from the French working group on perioperative hemostasis(GIHP)-September 2015", Anaesth Crit Care Pain Med, 36, pp.73~76 (2017)
28. Narouze S, "Interventional spine and pain procedures in patients on antiplatelet and anticoagulant medications(second edition) : guidelines from the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain", Reg Anesth Pain Med, 43, pp.225~262 (2018)
29. Tripodi A, "To measure or not to measure direct oral anticoagulants before surgery or invasive procedures : reply", J Thromb Haemost, 14, pp.2559~2561 (2016)
30. Calkins H, "2017 HRS", EHRA, APHRS, pp.SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation : executive summary, J Interv Card Electrophysiol[DOI]
31. Haeusler KG, "Left atrial catheter ablation and ischemic stroke", Stroke, 43, pp.265~270 (2012)
32. Kirchhof P, "2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS", Eur Heart J, 37, pp.2893~2962 (2016)
33. Cappato R, "Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation", Eur Heart J, 36, pp.1805~1811 (2015)
34. Calkins H, "Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation", N Engl J Med, 376, pp.1627~1636 (2017)
35. Kirchhof P, "Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation", Eur Heart J, 39, pp.2942~2955 (2018)
36. Steffel J, "First experience with edoxaban and atrial fibrillation ablation-insights from the ENGAGE AF-TIMI 48 trial", Int J Cardiol, 244, pp.192~195 (2017)
37. Kottmaier M, "Safety of uninterrupted periprocedural edoxaban versus phenprocoumon for patients who underwent left atrial catheter ablation procedures", Am J Cardiol, 121, pp.445~449 (2018)
38. Heidbuchel H, "Updated European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation", Europace, 17, pp.1467~1507 (2015)
39. Torn M, "Oral anticoagulation in surgical procedures : risks and recommendations", Br J Haematol, 123, pp.676~682 (2003)
40. Bassiouny M, "Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation", Circ Arrhythm Electrophysiol, 6, pp.460~466 (2013)
41. Di Biase L, "Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation : results from a multicenter study", Heart Rhythm, 12, pp.1162~1168 (2015)
42. Sticherling C, "Antithrombotic management in patients undergoing electrophysiological procedures : a European Heart Rhythm Association(EHRA)position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society(HRS), and Asia Pacific Heart Rhythm Society(APHRS)", Europace, 17, pp.1197~1214 (2015)
43. Beyer-Westendorf J, "Peri-interventional management of novel oral anticoagulants in daily care : results from the prospective dresden NOAC registry", Eur Heart J, 35, pp.1888~1896 (2014)
44. Douxfils J, "Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate", Thromb Haemost, 107, pp.985~997 (2012)
45. Douxfils J, "Laboratory testing in patients treated with direct oral anticoagulants : a practical guide for clinicians", J Thromb Haemost, 16, pp.209~219 (2018)
46. Douxfils J, "Assessment of the impact of rivaroxaban on coagulation assays : laboratory recommendations for the monitoring of rivaroxaban and review of the literature", Thromb Res, 130, pp.956~966 (2012)
47. van Ryn J, "Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor : interpretation of coagulation assays and reversal of anticoagulant activity", Thromb Haemost, 103, pp.1116~1127 (2010)
48. Lindhoff-Last E, "Assays for measuring rivaroxaban : their suitability and limitations", Ther Drug Monit, 32, pp.673~679 (2010)
49. Mani H, "Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant", Ther Drug Monit, 36, pp.624~631 (2014)
50. Kaess BM, "Comparison of safety of left atrial catheter ablation procedures for atrial arrhythmias under continuous anticoagulation with apixaban versus phenprocoumon", Am J Cardiol, 115, pp.47~51 (2015)
51. Auer J, "Interruption of non-vitamin K antagonist anticoagulants in patients undergoing planned invasive procedures : how long is long enough", Eur Heart J, 38, pp.2440~2443 (2017)
52. Kubitza D, "Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects", Curr Med Res Opin, 24, pp.2757~2765 (2008)
53. Frost C, "Apixaban, an oral, direct factor Xa inhibitor : single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects", Br J Clin Pharmacol, 75, pp.476~487 (2013)
54. Huisman MV, "Dabigatran etexilate for stroke prevention in patients with atrial fibrillation : resolving uncertainties in routine practice", Thromb Haemost, 107, pp.838~847 (2012)
55. Green R, "How long after drug ingestion is activated charcoal still effective", J Toxicol Clin Toxicol, 39, pp.601~605 (2001)
56. Peetermans M, "Idarucizumab for dabigatran overdose", Clin Toxicol(Phila), 54, pp.644~646 (2016)

관련 논문AI추천